Quality aspects of the tissue microarray technique in a population‐based cohort with ductal carcinoma in situ of the breast

Aims:  Tissue microarray (TMA) is an efficient technique for analysis of molecular markers. Prospectively collected samples have been reported to give excellent concordance between TMA data and corresponding whole‐sections. The aim was to evaluate the usefulness of TMA in a population‐based cohort of 213 women with ductal carcinoma in situ of the breast (DCIS).

[1]  P. Lal,et al.  Feasibility of Using Tissue Microarrays for the Assessment of HER-2 Gene Amplification by Fluorescence In Situ Hybridization in Breast Carcinoma , 2004, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[2]  A. Sapino,et al.  Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure , 2006, Virchows Archiv.

[3]  A. Tosteson,et al.  Pathologists' agreement with experts and reproducibility of breast ductal carcinoma-in-situ classification schemes. , 2000, The American journal of surgical pathology.

[4]  J. van der Velden,et al.  Validation of tissue microarray technology in endometrioid cancer of the endometrium , 2006, Journal of Clinical Pathology.

[5]  Ronald Simon,et al.  Tissue microarrays in cancer diagnosis , 2003, Expert review of molecular diagnostics.

[6]  G. Sauter,et al.  Tissue microarrays for comparing molecular features with proliferation activity in breast cancer , 2006, International journal of cancer.

[7]  N. Dallimore,et al.  Consistency in the observation of features used to classify duct carcinoma in situ (DCIS) of the breast , 2000, Journal of clinical pathology.

[8]  S. Swain,et al.  Ductal carcinoma in situ, complexities and challenges. , 2004, Journal of the National Cancer Institute.

[9]  L. Holmberg,et al.  Tumour markers in breast carcinoma correlate with grade rather than with invasiveness , 2001, British Journal of Cancer.

[10]  M. J. Silverstein,et al.  Prognostic classification of breast ductal carcinoma-in-situ , 1995, The Lancet.

[11]  M. García-Closas,et al.  Construction and Validation of Tissue Microarrays of Ductal Carcinoma In Situ and Terminal Duct Lobular Units Associated With Invasive Breast Carcinoma , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[12]  Manuel Salto-Tellez,et al.  Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. , 2003, Human pathology.

[13]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[14]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.

[15]  J. Cuzick.  Treatment of DCIS--results from clinical trials. , 2003, Surgical oncology.

[16]  R. Mansel,et al.  A critical appraisal of six modern classifications of ductal carcinoma in situ of the breast (DCIS): correlation with grade of associated invasive carcinoma , 1996, Histopathology.

[17]  M. Salto‐Tellez,et al.  Reliability of Tissue Microarrays in Detecting Protein Expression and Gene Amplification in Breast Cancer , 2003, Modern Pathology.

[18]  D. Rimm,et al.  Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.

[19]  M. J. van de Vijver,et al.  Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.

[20]  M. Fernö,et al.  Tissue microarray analyses of G1/S-regulatory proteins in ductal carcinoma in situ of the breast indicate that low cyclin D1 is associated with local recurrence , 2003, British Journal of Cancer.

[21]  H. Moch,et al.  Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.